Iain Dukes

Essentialis, Inc. develops therapeutic products in curing metabolic diseases. It operates as a pharmaceutical company focusing on the development of breakthrough medicines for the treatment of rare metabolic diseases where there is mortality and risk of cardiovascular and endocrine complications. The company was founded by Neil M. Cowen, Jeffrey A. Staffa and Thomas A. Glaze in 2004 and is headquartered in San Diego, CA.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

Part of Mabion SA, Biotech Consulting is a French company that provides business consulting services. The company is based in Cornier, France.

NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom.

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom.

Angiex, Inc. operates as a biotechnology company, which engages in the development of an antibody-drug conjugate therapy for cancer. It focuses on TM4SF1, a membrane glycoprotein of tetraspanin topology that was originally discovered as a protein expressed on many human epithelial tumor cells. The company was founded by Paul Jaminet, Harold Dvorak, and Shou-Ching Jaminet in 2015 and is headquartered in Cambridge, MA.

KaNDy Therapeutics Ltd. engages in the provision of a treatment of chronic debilitating female sex-hormone related conditions. Its product is NT-814 a non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms. The company was founded by Dr. Mike Trower and Mary Kerr in 2017 and is headquartered in Stevenage, the United Kingdom.

Part of Ikena Oncology, Inc., Arrys Therapeutics, Inc. provides treatments to cancer patients. The company is based in Boston, MA. The CEO of the company is Iain David Dukes.

Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA.

Kartos Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Redwood City, CA. Kartos Therapeutics, Inc. is focused on developing a potential MDM2 inhibitor for the treatment of various TP53 wild-type hematological malignancies and solid tumors. The company was founded by Wayne P. Rothbaum and Iain David Dukes, and the CEO is Jesse Seton McGreivy.

Viriom, Inc. is a biotechnology company based in San Diego, CA. The company focuses on developing innovative therapies for infectious diseases, including HIV and COVID-19. Viriom's mission is to improve the lives of patients by providing effective and accessible treatments. Iain David Dukes has been the CEO of the company since 2019, leading the team in their efforts to advance the development of their pipeline and bring new therapies to market.

NeRRe Therapeutics Holdings Ltd. is a British biotechnology company founded in 2017. The private company is based in Stevenage, UK. The company is engaged in research and development of biotechnology.

Gwynant Therapeutics develops new small molecules for oncology targets.

Trawsfynydd Therapeutics, Inc. engages in discovering and developing antiviral medicines. The company is located in the US.

Eilean Therapeutics LLC is a biopharmaceutical company based in Dover, DE. Eilean Therapeutics is focused on the discovery and development of first-in-class small molecule inhibitors that target escape mutations in hematologic and solid cancers. Eilean Therapeutics LLC is utilizing a proprietary hybrid AI platform to accelerate the execution of discovery and development of novel breakthrough medicines to maximize the clinical benefit when treating hematologic and solid malignancies. The company was founded in 2022 by John C. Byrd and is co-founded by OrbiMed, Torrey Pines Investment.